Enhancing the antibacterial activity of polymyxins using a nonantibiotic drug

Abstract

Malathy Krishnamurthy,1 Margaret M Lemmon,1 Evan M Falcinelli,1 Reuel A Sandy,1 Jennifer N Dootz,1 Tiffany M Mott,1 Sathish Rajamani,1,2 Kurt E Schaecher,3 Allen J Duplantier,1,4 Rekha G Panchal11Department of Target Discovery and Experimental Microbiology, Division of Molecular and Translational Sciences, United States Army Medical Research Institute of Infectious Diseases, Frederick, MD, USA; 2General Dynamics Information Technology, Frederick, MD, USA; 3Department of Pathology, Walter Reed National Military Medical Center, Bethesda, MD, USA; 4Cherokee Nation Assurance, Frederick, MD, USAPurpose: The rapid emergence of multidrug-resistant (MDR) bacteria and the lack of new therapies to eliminate them poses a major threat to global health. With the alarming rise in antimicrobial resistance (AMR), focus has now shifted to the use of the polymyxin class of antibiotics as the last line of defense for treatment of Gram-negative infections. Unfortunately, the growing resistance of bacteria against polymyxins is threatening the treatment of MDR infections, necessitating the need for novel strategies. The objective of this study was to determine if combination of polymyxin (polymyxin B or colistin) with a nonantibiotic small molecule AR-12, a celecoxib derivative that is devoid of cyclooxygenase 2 (COX-2) inhibitory activities, can be an effective strategy against polymyxin-resistant MDR bacteria.Methods: Growth inhibition studies, time-kill assays and permeability assays were conducted to investigate the effect of AR-12 on the antibacterial activity of polymyxins.Results: Growth studies were performed on a panel of polymyxin-resistant MDR strains using the combination of AR-12 with either colistin or polymyxin B. The combination treatment had no effect on strains that have inherent polymyxin resistance; however, AR-12 was effective in lowering the minimal inhibitory concentration (MIC) of polymyxins by 4–60-fold in several strains that had acquired polymyxin resistance. Time-kill assays using the combination of AR-12 and colistin with select MDR strains suggest rapid killing and bactericidal activity, while the permeability assays using fluorescently labeled dansylated polymyxin and 1-N-phenylnaphthylamine (NPN) in these MDR strains suggest that AR-12 can potentiate the antibacterial activity of polymyxins by possibly altering the bacterial outer membrane via modification of lipopolysaccharide and thereby improving the uptake of polymyxins.Conclusion: Our studies indicate that the combination of AR-12 and polymyxin is effective in targeting select Gram-negative bacteria that have acquired polymyxin resistance. Further understanding of the mechanism of action of AR-12 will provide new avenues for developing narrow-spectrum antibacterials to target select Gram-negative MDR bacteria. Importantly, our studies show that the use of nonantibiotic small molecules in combination with polymyxins is an attractive strategy to counter the growing resistance of bacteria to polymyxins.Keywords: Gram-negative, MDR bacteria, potentiator, antimicrobial resistance

Keywords

• Gram-negative
• MDR bacteria
• potentiator
• antimicrobial resistance